User login
Key clinical point: Compared with patients having metaplastic breast cancer (MpBC) who did not receive any chemotherapy, prognostic outcomes were significantly improved in those who received neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy.
Major finding: Compared with patients who did not receive any chemotherapy, the overall survival (OS) improved significantly in those who received adjuvant chemotherapy (hazard ratio [HR] 0.451; P < .001) or responded to NAC (HR 0.479; P < .001). Breast cancer-specific survival also improved in patients who received and responded to NAC or received adjuvant chemotherapy.
Study details: This study analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database and included 1186 patients with MpBC who received NAC (n = 181), adjuvant chemotherapy (n = 647), or did not receive any chemotherapy (n = 358).
Disclosures: This study was supported by the Science and Technology Innovation Plan of Shanghai Science and Technology Commission and the Obstetrics and Gynecology Hospital of Fudan University. The authors declared no conflicts of interest.
Source: Zhang M, Yuan J, Wang M, Zhang M, Chen H. Chemotherapy is of prognostic significance to metaplastic breast cancer. Sci Rep. 2024;14:1210. doi: 10.1038/s41598-024-51627-1 Source
Key clinical point: Compared with patients having metaplastic breast cancer (MpBC) who did not receive any chemotherapy, prognostic outcomes were significantly improved in those who received neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy.
Major finding: Compared with patients who did not receive any chemotherapy, the overall survival (OS) improved significantly in those who received adjuvant chemotherapy (hazard ratio [HR] 0.451; P < .001) or responded to NAC (HR 0.479; P < .001). Breast cancer-specific survival also improved in patients who received and responded to NAC or received adjuvant chemotherapy.
Study details: This study analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database and included 1186 patients with MpBC who received NAC (n = 181), adjuvant chemotherapy (n = 647), or did not receive any chemotherapy (n = 358).
Disclosures: This study was supported by the Science and Technology Innovation Plan of Shanghai Science and Technology Commission and the Obstetrics and Gynecology Hospital of Fudan University. The authors declared no conflicts of interest.
Source: Zhang M, Yuan J, Wang M, Zhang M, Chen H. Chemotherapy is of prognostic significance to metaplastic breast cancer. Sci Rep. 2024;14:1210. doi: 10.1038/s41598-024-51627-1 Source
Key clinical point: Compared with patients having metaplastic breast cancer (MpBC) who did not receive any chemotherapy, prognostic outcomes were significantly improved in those who received neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy.
Major finding: Compared with patients who did not receive any chemotherapy, the overall survival (OS) improved significantly in those who received adjuvant chemotherapy (hazard ratio [HR] 0.451; P < .001) or responded to NAC (HR 0.479; P < .001). Breast cancer-specific survival also improved in patients who received and responded to NAC or received adjuvant chemotherapy.
Study details: This study analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database and included 1186 patients with MpBC who received NAC (n = 181), adjuvant chemotherapy (n = 647), or did not receive any chemotherapy (n = 358).
Disclosures: This study was supported by the Science and Technology Innovation Plan of Shanghai Science and Technology Commission and the Obstetrics and Gynecology Hospital of Fudan University. The authors declared no conflicts of interest.
Source: Zhang M, Yuan J, Wang M, Zhang M, Chen H. Chemotherapy is of prognostic significance to metaplastic breast cancer. Sci Rep. 2024;14:1210. doi: 10.1038/s41598-024-51627-1 Source